HuGE Literature Finder
Records
1
-
6
| Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
| Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? Pharmacogenomics 2017 May . Taranu Adela, Colle Romain, Gressier Florence, El Asmar Khalil, Becquemont Laurent, Corruble Emmanuelle, Verstuyft Céli |
| Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry. Pharmacopsychiatry 2016 Apr . Berm E, Kok R, Hak E, Wilffert |
| Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and clinical neurosciences 2012 Oct 66 (6): 518-24. Nagai Goyo, Mihara Kazuo, Nakamura Akifumi, Suzuki Takeshi, Nemoto Kenji, Kagawa Shoko, Ohta Ikuya, Arakaki Hajime, Kondo Tsuyos |
| Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. Puerto Rico health sciences journal 2010 Sep 29 (3): 299-304. González-Tejera Gloria, Gaedigk Andrea, Corey Sus |
| CYP 2D6 polymorphism and antipsychotic therapy. Psychiatria Danubina 2008 Sep 20 (3): 369-71. Plesnicar Blanka Kores, Dolzan Vita, Zalar Boj |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 26, 2022
- Content source: